Phase 3 N=55 Efficacy and Safety Study of a Recombinant Protein-Free Manufactured Factor VIII (rAHF-PFM) in Previously Untreated Hemophilia A Patients
Hemophilia A
Primary: Factor VIII Inhibitor Development — 29.1 percentage
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=391 Long-term Safety Study of Open-label Pramipexole ER in Patients With Advanced PD
Parkinson Disease
Primary: Percentage of Patients With Adverse Events, Adverse Drug Reactions, Serious Adverse Events — 85.3; 83.7; 79.9; 52.7 Percentage of participants
Phase 3 N=36 Impact of Metformin in Teens With Polycystic Ovary Syndrome (PCOS) on Oral Contraceptive Therapy
Polycystic Ovary Syndrome
Primary: Reduction in Abdominal Fat as Measured by Waist Circumference. — -3.9; -1.4 cm
Phase 3 N=190 Long Term Follow-up Study With Keppra XR (Levetiracetam XR) for Partial Seizures
Epilepsy
Primary: Number of Subjects Who Experienced at Least 1 Treatment Emergent Adverse Event During the Actual Treatment Period (6 Months-2 Years) — 126 number of subjects
Phase 3 N=820 Safety and Efficacy of Aliskiren in Post Myocardial Infarction Patients (ASPIRE)
Myocardial Infarction
Primary: Core Study: Change From Baseline in Left Ventricular End Systolic Volume (LVESV) as Measured by Echocardiography at End of Study. — -3.14; -4.13 mL
Phase 3 N=345 Laser-Ranibizumab-Triamcinolone for Proliferative Diabetic Retinopathy
Proliferative Diabetic Retinopathy · Diabetic Macular Edema
Primary: Change in Electronic Early Treatment Diabetic Retinopathy Study Visual Acuity Letter Score From Baseline to 14 Weeks — -4; 1; 2 Letter Score — p=<.001
Phase 3 N=854 Laser-Ranibizumab-Triamcinolone for Diabetic Macular Edema
Diabetic Retinopathy · Diabetic Macular Edema
Primary: Mean Change in Visual Acuity (Letters) From Baseline to 1 Year Adjusted for Baseline Visual Acuity — 3; 9; 9; 4 Letters — p=<0.001
Phase 3 N=233 Follow-up to Welcome Study C87042 [NCT00308581] Examining Certolizumab Pegol (CDP870) in Subjects With Crohn's Disease
Crohn's Disease
Primary: Occurrence of at Least One Study-emergent Adverse Event During the Study (Maximum 164 Weeks) — 92.6 percentage of participants
Phase 3 N=678 TMC278-TiDP6-C215: A Clinical Trial in Treatment Naive HIV-subjects Patients Comparing TMC278 to Efavirenz in Combination With 2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors
HIV Infections · HIV-1
Primary: Number of Participants With Virological Response (Intent-to-Treat - Time to Loss of Virologic Response [TLOVR], <50 Copies Per mL) at Week 48 — 291; 276; 24; 18…
Phase 3 N=288 Efficacy and Safety of Alogliptin Used Combination With Metformin in Participants With Type 2 Diabetes in Japan
Type 2 Diabetes Mellitus
Primary: Change From Baseline in Glycosylated Hemoglobin (Week 12). — -0.54; -0.64; 0.21 percentage of Glycosylated Hemoglobin
Phase 3 N=47 Evaluation of the Bio-Seal Biopsy Track Plug
Lung Cancer
Primary: Number of Participants With Absence of Pneumothoraces — 18; 18 Participants
Phase 3 N=230 Efficacy and Safety of Alogliptin Used in Combination With α-glucosidase Inhibitor in Participants With Type 2 Diabetes in Japan
Type 2 Diabetes Mellitus
Primary: Change From Baseline in Glycosylated Hemoglobin (Week 12). — 0.04; -0.96; -0.91 percentage of Glycosylated Hemoglobin
Phase 3 N=690 TMC278-TiDP6-C209: A Clinical Trial in Treatment Naive HIV-1 Patients Comparing TMC278 to Efavirenz in Combination With Tenofovir + Emtricitabine.
HIV Infections · HIV-1 · Human Immunodeficiency Virus Type 1
Primary: Number of Participants With Virological Response (Intent-to-Treat - Time to Loss of Virologic Response [TLOVR], <50 Copies/ml) at Week 48 — 287; 285; 38; 15 Participants…
Phase 3 N=115 Clinical Evaluation to Confirm Safety and Efficacy of Sinuplasty in the Paranasal Sinuses (CLEAR)
Chronic Sinusitis
Primary: Number of Sinuses With Patency of Sinus Ostium After Sinuplasty — 247 Sinuses
Phase 3 N=98 Growth Hormone Treatment in Children Born Small for Gestational Age (SGA)
Foetal Growth Problem · Small for Gestational Age
Primary: Change in Height Standard Deviation Score (SDS) for Chronological Age (CA) at Week 260 - Subjects Received NN220 Treatment for 5 Years — -2.9488; -2.9047; 1.2066; 2.0247…